TestwBankwForwClayton’swBasicwPharmacologywforwNursesw19thwEditio 1
n
COMPELETE TESTBANK w
TESTBANK FOR CLAYON’S BASIC PHARMACOLOGY F
w w w w w
OR NURSES 19TH EDITION/ WILLIHNGANZ VERIFIED Q
w w w w w w
UESTIONS AND ANSWERS WITH 2024 UPDATES (ALL C
w w w w w w w
HAPTERS INLUDED 1-48) w w
,TestwBankwForwClayton’swBasicwPharmacologywforwNursesw19thwEditio 2
n
Chapter 01: Drug Definitions, Standards, and Information Sources Willihngan
w w w w w w w w
z: Clayton’s Basic Pharmacology for Nurses, 19th Edition
w w w w w w w
1. WhichwnamewidentifieswawdrugwlistedwbywthewUSwFoodwDru
gwAdministrationw(FDA)?
a. Bran
b. Nonproprietar
c. Official
d. Trademark
ANS:
Thewofficialwnamewiswthewnamewunderwwhichwawdrugwiswlistedwby
wthewFDA.wThewbrandwname,worwtrademark, wiswthewnamewgivenwt
owawdrugwbywitswmanufacturer.wThewnonproprietary,worwgeneric,w
namewiswprovidedwbywthewUnitedwStateswAdoptedwNameswCoun
cil.
CognitivewLevel:wKnowledge REF:w p.w9
OBJ:w1NAT:wNCLEXwClientwNeedswCategory:wSafe,wEffectivewCar
ewEnvironmentwTOP:w NursingwProcesswStep:wAssessment
CON:w
PatientwEducation
2. Whichwsourcewcontainswinformationwspecificwtownutritionalwsupplements?
a. USPwDictionarywofwUSANw &wInternationalwDrugwNames
b. NaturalwMedicineswComprehensivewDatabase
c. UnitedwStateswPharmacopoeia/NationalwFormularyw(USPwNF)
d. DrugwInteractionwFacts
ANS:wC
UnitedwStateswPharmacopoeia/NationalwFormularywcontainswinformationwspecificwtownutritionalwsup
plements.wUSPwDictionarywofwUSANw&wInternationalwDrugwNameswiswawcompilationwofwdrugwnames
,wpronunciationwguide,wandwpossiblewfuturewFDAwapprovedwdrugs;witwdoeswnotwincludewnutritionalws
upplements.wNaturalwMedicineswComprehensivewDatabasewcontains
evidence-
basedwinformationwonwherbalwmedicineswandwherbalwcombinationwproducts;witwdoeswnotwincludew
informationwspecificwtownutritionalwsupplements.wDrugwInteractionwFactswcontainswcomprehen
sivewinformationwonwdrugwinteractionwfacts;witwdoeswnotwincludewnutritionalwsupplements.
DIF: CognitivewLevel:wKnowledge REF:w p.w4
OBJ:w3wNAT:w NCLEXwClientwNeedswCategory:wPhysiologicalwInt
egrity
TOP:w NursingwProcesswStep:wAssessment CON:w Nutritionw|wPatientwEducation
3. Whichwdrugwreferencewcontainswdrugwmonographswthatwdescribewallwdrugswinwawtherapeuticwclass?
a. DrugwFactswandwComparisons
,TestwBankwForwClayton’swBasicwPharmacologywforwNursesw19thwEditio 3
n
b. DrugwInteractionwFacts
c. HandbookwonwInjectablewDrugs
d. Martindale—ThewCompletewDrugwReference
ANS:wA
DrugwFactswandwComparisonswcontainswdrugwmonographswthatwdescribewallwdrugswinwa
wtherapeuticwclass.wMonographs warewformatted waswtableswtowallowwcomparisonwofwsimila
rwproducts,wbrandwnames,wmanufacturers,wcostwindices,wandwavailablewdosagewformswO
nlinewversionwiswavailable.
DIF: CognitivewLevel:wKnowledge REF:w p.w4wTablew1.2
OBJ:w w 3 NAT:w NCLEXwClientwNeedswCategory:wPhysiologicalwIntegrity
TOP:w NursingwProcesswStep:wAssessment CON:w Safetyw|wPatientwEducationw|wClinicalwJudgment
4. Whichwdrugwreferencewcontainswmonographswaboutwvirtuallyweverywsingle-
entitywdrugwavailablewinwthewUnitedwStateswandwdescribeswtherapeuticwuseswofwdrugs,wincludin
gwapprovedwandwunapprovedwuses?
a. Martindale:wThewCompletewDrugwReference
b. AHFSwDrugwInformation
c. DrugwReference
d. DrugwFactswandwComparisons
ANS:wB
AHFSwDrugwInformationwcontainswmonographswaboutwvirtuallyweverywsingle-
entitywdrugwavailablewinwthewUnitedwStateswandwdescribeswtherapeuticwuseswofwdrugs,wincludingwa
pprovedwandwunapprovedwuses.
DIF: CognitivewLevel:wKnowledge REF:w p.w4wTablew1.2
OBJ:w w 3 NAT:w NCLEXwClientwNeedswCategory:wPhysiologicalwIntegrity
TOP:w NursingwProcesswStep:wPlanning CON:w Safetyw|wPatientwEducationw|wClinicalwJudgment
5. Whichwonlinewdrugwreferencewmakeswavailablewtowhealthcarewproviderswandwthewpublicwawst
andard,wcomprehensive,wup-to-datewlookwupwandwdownloadablewresourcewaboutwmedicines?
a. AmericanwDrugwIndex
b. AmericanwHospitalwFormulary
c. DailyMed
d. DrugwReference
ANS:wC
DailyMedwmakeswavailablewtowhealthcarewproviderswandwthewpublicwawstandard,wcomprehensiv
e,wup-to-
datewlookwupwandwdownloadablewresourcewaboutwmedicines.wThewAmericanwDrugwIndexwiswnotw
appropriatewforwpatientwuse.wThewAmericanwHospitalwFormularywiswnotwappropriatewforwpatien
twuse.wThewdrugwreferencewiswnotwappropriatewforwpatientwuse.
DIF: CognitivewLevel:wKnowledge REF:w p.w3w|wp.w4
OBJ:w3wNAT:w NCLEXwClientwNeedswCategory:wPhysiologicalwInt
egrity
TOP:w NursingwProcesswStep:wImplementation
CON:w Safetyw|wPatientwEducationw|wClinicalwJudgment
6. WhichwlegislationwauthorizeswthewFDAwtowdeterminewthewsafetywofwawdrugwbeforewitswmarketing?
a. FederalwFood,wDrug,wandwCosmeticwActw(1938)
b. DurhamwHumphreywAmendmentw(1952)
, TestwBankwForwClayton’swBasicwPharmacologywforwNursesw19thwEditio 4
n
c. ControlledwSubstanceswActw(1970)
d. KefauverwHarriswDrugwAmendmentw(1962)
ANS:wA
ThewFederalwFood,wDrug,wandwCosmeticwActwofw1938wauthorizedwthewFDAwtowdeterminewthewsa
fetywofwallwdrugswbeforewmarketing.wLaterwamendmentswandwactswhelpedwtightenwFDAwcontrolw
andwensurewdrugwsafety.wThewDurhamwHumphreywAmendmentwdefineswthewkindswofwdrugswthat
wcannot wbewused wsafelywwithoutwmedical wsupervisionwandwrestricts wtheirwsalewtowprescription wby
wawlicensedwpractitioner.wThewControlledwSubstanceswActwaddresseswonlywcontrolledwsubstances w
andwtheirwcategorization.wThewKefauverwHarriswDrugwAmendmentwensureswdrugwefficacywandwg
reaterwdrugwsafety.wDrugwmanufacturerswarewrequiredwtowprovewtowthewFDAwtheweffectivenesswo
fwtheirwproductswbeforewmarketingwthem.
DIF: CognitivewLevel:wKnowledge REF:w p.w5wTablewl.3
OBJ:w 5
NAT:wNCLEXwClientwNeedswCategory:wPhysiologicalwIntegrit
ywTOP:w NursingwProcesswStep:wAssessment
CON:w Safetyw|wPatientwEducationw|wEvidencew|wHealthwCarewLaw
7. Whichwclassificationwdoeswmeperidinew(Demerol)wfallwunder?
a. I
b. II
c. III
d. IV
ANS:wB
Meperidinew(Demerol)wiswawSchedulewIIwdrug;witwhaswawhighwpotentialwforwabusewandwmaywleadw
towseverewpsychologicalwandwphysicalwdependence.wSchedulewIwdrugswhavewhighwpotentialwforwa
busewandwnowrecognizedwmedicalwuse.wSchedulewIIIwdrugswhavewsomewpotentialwforwabuse.wUse
wmaywleadwtowlowwtowmoderatewphysical wdependenceworwhighwpsychological wdependence.wSche
dulewIVwdrugswhavewlowwpotentialwforwabuse.wUsewmaywleadwtowlimitedwphysicalworwpsychologi
calwdependence.
DIF: CognitivewLevel:wKnowledge REF:w p.w10
OBJ:w2wNAT:w NCLEXwClientwNeedswCategory:wSafe,wEffectivewC
arewEnvironment
TOP:w NursingwProcesswStep:wAssessment CON:w PatientwEducationw|wAddictionw|wPain
8. WhichwactionwwouldwthewFDAwtakewtowexpeditewdrugwdevelopmentwandwapprovalwforwanwoutbre
akwofwsmallpox?
a. Listwsmallpoxwaswawhealthworphanwdisease.
b. Omitwthewpreclinicalwresearchwphase.
c. Extendwthewclinicalwresearchwphase.
d. Fastwtrackwthewinvestigationalwdrug.
ANS:wD
OncewthewInvestigationalwNewwDrugwApplicationwhaswbeenwapproved,wthewdrugwcanwreceivewhi
ghestwprioritywwithinwthewagency,wwhichwiswcalledwfastwtracking.wAwsmallpoxwoutbreakwwouldw
becomewawprioritywconcernwinwthewworld.wOrphanwdiseaseswarewnotwresearchedwinwawprioritywma
nner.wPreclinicalwresearchwiswnotwomitted.wExtendingwanywphasewofwthewresearchwwouldwmeanwa
wlongerwtimewtowdevelop wawvaccine.wThewFDAwmust wensurewthatwallwphaseswofwthewpreclinical wan
dwclinicalwresearchwphasewhavewbeenwcompletedwinwawsafewmanner.
DIF: CognitivewLevel:wKnowledge REF:w p.w7 OBJ:w 5
n
COMPELETE TESTBANK w
TESTBANK FOR CLAYON’S BASIC PHARMACOLOGY F
w w w w w
OR NURSES 19TH EDITION/ WILLIHNGANZ VERIFIED Q
w w w w w w
UESTIONS AND ANSWERS WITH 2024 UPDATES (ALL C
w w w w w w w
HAPTERS INLUDED 1-48) w w
,TestwBankwForwClayton’swBasicwPharmacologywforwNursesw19thwEditio 2
n
Chapter 01: Drug Definitions, Standards, and Information Sources Willihngan
w w w w w w w w
z: Clayton’s Basic Pharmacology for Nurses, 19th Edition
w w w w w w w
1. WhichwnamewidentifieswawdrugwlistedwbywthewUSwFoodwDru
gwAdministrationw(FDA)?
a. Bran
b. Nonproprietar
c. Official
d. Trademark
ANS:
Thewofficialwnamewiswthewnamewunderwwhichwawdrugwiswlistedwby
wthewFDA.wThewbrandwname,worwtrademark, wiswthewnamewgivenwt
owawdrugwbywitswmanufacturer.wThewnonproprietary,worwgeneric,w
namewiswprovidedwbywthewUnitedwStateswAdoptedwNameswCoun
cil.
CognitivewLevel:wKnowledge REF:w p.w9
OBJ:w1NAT:wNCLEXwClientwNeedswCategory:wSafe,wEffectivewCar
ewEnvironmentwTOP:w NursingwProcesswStep:wAssessment
CON:w
PatientwEducation
2. Whichwsourcewcontainswinformationwspecificwtownutritionalwsupplements?
a. USPwDictionarywofwUSANw &wInternationalwDrugwNames
b. NaturalwMedicineswComprehensivewDatabase
c. UnitedwStateswPharmacopoeia/NationalwFormularyw(USPwNF)
d. DrugwInteractionwFacts
ANS:wC
UnitedwStateswPharmacopoeia/NationalwFormularywcontainswinformationwspecificwtownutritionalwsup
plements.wUSPwDictionarywofwUSANw&wInternationalwDrugwNameswiswawcompilationwofwdrugwnames
,wpronunciationwguide,wandwpossiblewfuturewFDAwapprovedwdrugs;witwdoeswnotwincludewnutritionalws
upplements.wNaturalwMedicineswComprehensivewDatabasewcontains
evidence-
basedwinformationwonwherbalwmedicineswandwherbalwcombinationwproducts;witwdoeswnotwincludew
informationwspecificwtownutritionalwsupplements.wDrugwInteractionwFactswcontainswcomprehen
sivewinformationwonwdrugwinteractionwfacts;witwdoeswnotwincludewnutritionalwsupplements.
DIF: CognitivewLevel:wKnowledge REF:w p.w4
OBJ:w3wNAT:w NCLEXwClientwNeedswCategory:wPhysiologicalwInt
egrity
TOP:w NursingwProcesswStep:wAssessment CON:w Nutritionw|wPatientwEducation
3. Whichwdrugwreferencewcontainswdrugwmonographswthatwdescribewallwdrugswinwawtherapeuticwclass?
a. DrugwFactswandwComparisons
,TestwBankwForwClayton’swBasicwPharmacologywforwNursesw19thwEditio 3
n
b. DrugwInteractionwFacts
c. HandbookwonwInjectablewDrugs
d. Martindale—ThewCompletewDrugwReference
ANS:wA
DrugwFactswandwComparisonswcontainswdrugwmonographswthatwdescribewallwdrugswinwa
wtherapeuticwclass.wMonographs warewformatted waswtableswtowallowwcomparisonwofwsimila
rwproducts,wbrandwnames,wmanufacturers,wcostwindices,wandwavailablewdosagewformswO
nlinewversionwiswavailable.
DIF: CognitivewLevel:wKnowledge REF:w p.w4wTablew1.2
OBJ:w w 3 NAT:w NCLEXwClientwNeedswCategory:wPhysiologicalwIntegrity
TOP:w NursingwProcesswStep:wAssessment CON:w Safetyw|wPatientwEducationw|wClinicalwJudgment
4. Whichwdrugwreferencewcontainswmonographswaboutwvirtuallyweverywsingle-
entitywdrugwavailablewinwthewUnitedwStateswandwdescribeswtherapeuticwuseswofwdrugs,wincludin
gwapprovedwandwunapprovedwuses?
a. Martindale:wThewCompletewDrugwReference
b. AHFSwDrugwInformation
c. DrugwReference
d. DrugwFactswandwComparisons
ANS:wB
AHFSwDrugwInformationwcontainswmonographswaboutwvirtuallyweverywsingle-
entitywdrugwavailablewinwthewUnitedwStateswandwdescribeswtherapeuticwuseswofwdrugs,wincludingwa
pprovedwandwunapprovedwuses.
DIF: CognitivewLevel:wKnowledge REF:w p.w4wTablew1.2
OBJ:w w 3 NAT:w NCLEXwClientwNeedswCategory:wPhysiologicalwIntegrity
TOP:w NursingwProcesswStep:wPlanning CON:w Safetyw|wPatientwEducationw|wClinicalwJudgment
5. Whichwonlinewdrugwreferencewmakeswavailablewtowhealthcarewproviderswandwthewpublicwawst
andard,wcomprehensive,wup-to-datewlookwupwandwdownloadablewresourcewaboutwmedicines?
a. AmericanwDrugwIndex
b. AmericanwHospitalwFormulary
c. DailyMed
d. DrugwReference
ANS:wC
DailyMedwmakeswavailablewtowhealthcarewproviderswandwthewpublicwawstandard,wcomprehensiv
e,wup-to-
datewlookwupwandwdownloadablewresourcewaboutwmedicines.wThewAmericanwDrugwIndexwiswnotw
appropriatewforwpatientwuse.wThewAmericanwHospitalwFormularywiswnotwappropriatewforwpatien
twuse.wThewdrugwreferencewiswnotwappropriatewforwpatientwuse.
DIF: CognitivewLevel:wKnowledge REF:w p.w3w|wp.w4
OBJ:w3wNAT:w NCLEXwClientwNeedswCategory:wPhysiologicalwInt
egrity
TOP:w NursingwProcesswStep:wImplementation
CON:w Safetyw|wPatientwEducationw|wClinicalwJudgment
6. WhichwlegislationwauthorizeswthewFDAwtowdeterminewthewsafetywofwawdrugwbeforewitswmarketing?
a. FederalwFood,wDrug,wandwCosmeticwActw(1938)
b. DurhamwHumphreywAmendmentw(1952)
, TestwBankwForwClayton’swBasicwPharmacologywforwNursesw19thwEditio 4
n
c. ControlledwSubstanceswActw(1970)
d. KefauverwHarriswDrugwAmendmentw(1962)
ANS:wA
ThewFederalwFood,wDrug,wandwCosmeticwActwofw1938wauthorizedwthewFDAwtowdeterminewthewsa
fetywofwallwdrugswbeforewmarketing.wLaterwamendmentswandwactswhelpedwtightenwFDAwcontrolw
andwensurewdrugwsafety.wThewDurhamwHumphreywAmendmentwdefineswthewkindswofwdrugswthat
wcannot wbewused wsafelywwithoutwmedical wsupervisionwandwrestricts wtheirwsalewtowprescription wby
wawlicensedwpractitioner.wThewControlledwSubstanceswActwaddresseswonlywcontrolledwsubstances w
andwtheirwcategorization.wThewKefauverwHarriswDrugwAmendmentwensureswdrugwefficacywandwg
reaterwdrugwsafety.wDrugwmanufacturerswarewrequiredwtowprovewtowthewFDAwtheweffectivenesswo
fwtheirwproductswbeforewmarketingwthem.
DIF: CognitivewLevel:wKnowledge REF:w p.w5wTablewl.3
OBJ:w 5
NAT:wNCLEXwClientwNeedswCategory:wPhysiologicalwIntegrit
ywTOP:w NursingwProcesswStep:wAssessment
CON:w Safetyw|wPatientwEducationw|wEvidencew|wHealthwCarewLaw
7. Whichwclassificationwdoeswmeperidinew(Demerol)wfallwunder?
a. I
b. II
c. III
d. IV
ANS:wB
Meperidinew(Demerol)wiswawSchedulewIIwdrug;witwhaswawhighwpotentialwforwabusewandwmaywleadw
towseverewpsychologicalwandwphysicalwdependence.wSchedulewIwdrugswhavewhighwpotentialwforwa
busewandwnowrecognizedwmedicalwuse.wSchedulewIIIwdrugswhavewsomewpotentialwforwabuse.wUse
wmaywleadwtowlowwtowmoderatewphysical wdependenceworwhighwpsychological wdependence.wSche
dulewIVwdrugswhavewlowwpotentialwforwabuse.wUsewmaywleadwtowlimitedwphysicalworwpsychologi
calwdependence.
DIF: CognitivewLevel:wKnowledge REF:w p.w10
OBJ:w2wNAT:w NCLEXwClientwNeedswCategory:wSafe,wEffectivewC
arewEnvironment
TOP:w NursingwProcesswStep:wAssessment CON:w PatientwEducationw|wAddictionw|wPain
8. WhichwactionwwouldwthewFDAwtakewtowexpeditewdrugwdevelopmentwandwapprovalwforwanwoutbre
akwofwsmallpox?
a. Listwsmallpoxwaswawhealthworphanwdisease.
b. Omitwthewpreclinicalwresearchwphase.
c. Extendwthewclinicalwresearchwphase.
d. Fastwtrackwthewinvestigationalwdrug.
ANS:wD
OncewthewInvestigationalwNewwDrugwApplicationwhaswbeenwapproved,wthewdrugwcanwreceivewhi
ghestwprioritywwithinwthewagency,wwhichwiswcalledwfastwtracking.wAwsmallpoxwoutbreakwwouldw
becomewawprioritywconcernwinwthewworld.wOrphanwdiseaseswarewnotwresearchedwinwawprioritywma
nner.wPreclinicalwresearchwiswnotwomitted.wExtendingwanywphasewofwthewresearchwwouldwmeanwa
wlongerwtimewtowdevelop wawvaccine.wThewFDAwmust wensurewthatwallwphaseswofwthewpreclinical wan
dwclinicalwresearchwphasewhavewbeenwcompletedwinwawsafewmanner.
DIF: CognitivewLevel:wKnowledge REF:w p.w7 OBJ:w 5
